LUNG (Pulmonx Corporation) Market Analysis: Undervalued MedTech with Mixed Signals

Quick Overview

Pulmonx (LUNG) trades at $2.03 as of October 31, 2025, with a negative P/E ratio (-1.27) and small market cap ($82.6M). Recent analyst upgrades and a management shakeup dominate headlines, while technical indicators show caution. Fundamental scores suggest potential value, but debt and weak equity returns weigh down long-term confidence.

Key News Sentiment

1. Analyst Optimism Amid Lower Targets

• Lake Street and D. Boral Capital kept "Buy" ratings but slashed price targets (from $8 → $4 and $16 → $14).
• Why it matters: Analysts see long